Supramolecular coiled-coil peptide platform for site-specific antibody drug conjugate engineering
Antibody conjugates play a central role across multiple healthcare sectors with a prime example being antibody-drug conjugates (ADCs). Although widely used lysine and hinge cysteine conjugation methods yield products, the lack of site-specificity and spatial control along with the highly heterogeneous composition are significant limitations. Herein, we describe a facile supramolecular assembly method based on heterodimer coiled-coil formation for site-specific antibody conjugation that perseveres antibody antigen binding sites for target engagement. The platform method affords uniform loading of diverse payloads including anti-cancer agents, polymers, enzymes, fluorophores, etc. under mild aqueous conditions. Further, the facile convergent approach capitalizes on the independent strengths and flexibility of protein expression and peptide chemistry culminating in a final self-assembly step. An ADC loaded with monomethyl auristatin E targeting ErbB2/Her2 positive tumors significantly reduces tumor volume in a human ovarian cancer xenograft model outperforming the antibody alone with validated performance against a best-in-class therapeutic.
Authors
- Alina Ringaci (ORCID: https://orcid.org/0000-0001-6951-4032)
- Ting‐Yu Shih (ORCID: https://orcid.org/0000-0003-1733-0447)
- Mark W. Grinstaff
Institutions
- Boston University (US)
- Boston University Academy (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-03-02
- DOI
- https://doi.org/10.1038/s41467-026-70094-y
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pharmaceutical Research and Manufacturers of America Foundation
- National Institutes of Health